I recently had an in depth discussion with Maynard Breslow of Dank Discussions Podcast. We discussed a number of important topics currently facing the cannabis industry.
Category: Marijuana / Cannabis
A physician’s education about cannabis medicine, and her patient’s treatment options, should not depend on their state of residence. Patient access should be based on sound science and physicians should receive comprehensive and uniform education regardless of the state in which they practice.
The notion that impairment can be assumed or not based solely on specific concentrations of THC or its metabolites in a driver’s blood or urine is plainly wrong.
The American Journal of Endocannabinoid Medicine (AJEM) is the only printed, peer-reviewed, medical cannabis journal in North America. AJEM’s mission is to create, collect, and disseminate credible cannabis research data.
If cannabis stores close, the state of Oregon would be depriving many patients who rely on retail cannabis stores access to their medicine. If retail cannabis stores remain open, does it make sense to limit access to medicinal patents?
Trademark registration is not simply a matter of racing to the USPTO to register a word or phrase that you wish to have exclusive rights to, even if you were the first to use the word or phrase.
As a service to our current clients and readers during these difficult times, we are offering a free 20-minute phone call to address your pressing issues – no strings attached.
For my talk, I compared and contrasted the hemp and CBD regulatory regimes in Europe and US. Although they parallel each other in some respects, particularly policy, they are fundamentally different in their approaches.
2020 will be a historic and transformative year for cannabis, particularly for hemp and CBD. Here are my top 5 predictions.